Ardelyx, Inc.

NasdaqGM ARDX

Ardelyx, Inc. Operating Income for the Trailing 12 Months (TTM) ending September 30, 2024: USD -64.06 M

Ardelyx, Inc. Operating Income is USD -64.06 M for the Trailing 12 Months (TTM) ending September 30, 2024, a -176.76% change year over year. Operating income is the profit earned by a company from its normal business operations before interest and taxes are deducted.

Ardelyx, Inc. Operating Income for the Trailing 12 Months (TTM) ending September 30, 2023 was USD -23.15 M, a 79.18% change year over year.
Ardelyx, Inc. Operating Income for the Trailing 12 Months (TTM) ending September 30, 2022 was USD -111.17 M, a 24.22% change year over year.
Ardelyx, Inc. Operating Income for the Trailing 12 Months (TTM) ending September 30, 2021 was USD -146.72 M, a -78.95% change year over year.
Ardelyx, Inc. Operating Income for the Trailing 12 Months (TTM) ending September 30, 2020 was USD -81.98 M, a 17.84% change year over year.

Key data

Date	Operating Income	EBIT	EBITDA	Net Income

NasdaqGM: ARDX

Ardelyx, Inc.

CEO	Mr. Michael G. Raab
IPO Date	June 19, 2014
Location	United States
Headquarters	400 Fifth Avenue
Employees	267
Sector	Healthcare
Industries Pharmaceuticals Biotechnology Chemicals & Advanced Materials Clinical Trials Drugstores & Retail Pharmacies Fertilizers Non-Alcoholic Beverages Pet Food

Description

Ardelyx, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines to treat gastrointestinal and cardiorenal therapeutic areas in the United States and internationally. The company's lead product candidate is tenapanor, which has completed Phase III clinical trial for the treatment of patients with irritable bowel syndrome with constipation, as well as in Phase III clinical trial to control serum phosphorus in adult patients with chronic kidney disease (CKD)on dialysis, or hyperphosphatemia. It is also developing RDX013, a potassium secretagogue, for the treatment of elevated serum potassium, or hyperkalemia, a problem among certain patients with kidney and/or heart disease; and RDX020, an early-stage program in metabolic acidosis, a serious electrolyte disorder in patients with CKD. The company has agreements with Kyowa Kirin in Japan, Fosun Pharmaceutical Industrial Development Co. Ltd. in China, and Knight Therapeutics, Inc. in Canada for the development and commercialization of tenapanor in their respective territories. The company was formerly known as Nteryx, Inc. and changed its name to Ardelyx, Inc. in June 2008. Ardelyx, Inc. was incorporated in 2007 and is headquartered in Waltham, Massachusetts.

Key trends

Past 5 years